Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Staff exchange2015–2019

PRISAR · Preclinical Intra-Operative Image-Guided Surgery and Post-Operative Radiotherapy of Tumours

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2015-02-01 → 2019-01-31
EU contribution
€2,430,000
Participants
14
Scheme
MSCA-RISE

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

Preclinical Intra-Operative Image-Guided Surgery and Post-Operative Radiotherapy of Tumours

Pancreatic cancer is a major cause of cancer-associated mortality, with a dismal overall prognosis that has remained unchanged for many decades. There are several factors that contribute to the poor prognosis of patients with pancreatic cancer. The most important point is that due to the lack of disease-associated symptoms, approximately 50-60% of the patients already have locally advanced or metastatic disease at the time of diagnosis. The median survival of patients with metastatic pancreatic cancer is 3 months. Medical imaging has several important roles to personalize oncological management to the individual patient, ranging from initial diagnosis and staging towards early monitoring of therapy response and assessment of systemic control in metastatic patients. However, adequate visualization of the primary tumour and metastatic lesions using current imaging techniques and protocols is challenging in patients with pancreatic cancer. In a considerable number of patients, the primary tumour cannot be visualized. PRISAR stands for Preclinical Intraoperative Image-Guided Surgery and Postoperative Radionuclide therapy of Tumours and in this context, intraoperative fluorescence imaging is a promising technique which potentially allows a better detection of tumor cells left at the resection margins. Fluorescence guided surgery is the first part of PRISAR and can already lead to an enormous improvement in survival rates.

Data: CORDIS, © European Union

Project objective

The main objective and basic concept of our proposal is to improve intra-operative and post-operative targeted surgical probes and new detection systems for surgical intervention of cancer. The work revolves around the mobility of clinicians, scientists and technologists between twelve consortium partners and across four different countries. The goal is the implementation of inter-disciplinary, inter-sector, cross-training of personnel. As a consequence, this will serve to accelerate the development of improved imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. The hypothesis is that if we can develop a hybrid probe for both targeted image-guided surgery and post-operative molecular radiotherapy, we would be implementing a revolutionary imaging and therapeutic approach for oncology surgeons to help their patients by improving better overall survival and quality of life for the patient. There are four key objectives within this project: 1) synthesis of a near infra-red fluorescence (NIRF)-dye conjugated to a peptide that is targeted towards a tumour associated antigen, 2) deliver a novel clinical optoacoustic handheld camera to detect the fluorescence probe in deep tissue, 3) validate the probe/target combination across the subcellular, cellular, endoscopic and macroscopic levels with state-of-art technologies, and 4) develop the probe further by targeting a radionuclide entity to the fluorescent construct for postoperative radiotherapy. Surgeons would have a more definitive reference for resection, if the tumour margin can be clearly defined. If this can be achieved, the impact would be (a) reduced recurrence rates in patients by lowering the risk of residual tumour tissue remaining after surgery and as a consequence improve survival, (b) minimised removal of healthy tissues, c) reduced patient morbidity and hospital stay and d) significant health cost benefits.

Original text from CORDIS.

Participants

  • PERCUROS BV · 's-Gravenhage (Den Haag)CoordinatorNetherlands
  • ACADEMISCH ZIEKENHUIS LEIDEN · LeidenNetherlands
  • ANTIBODIES FOR RESEARCH APPLICATIONS BV · GoudaNetherlands
  • ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM · RotterdamNetherlands
  • GAMMA TECHNOLOGIES LIMITED · CamberleyCity levelUnited Kingdom
  • ITHERA MEDICAL GMBH · MunchenGermany
  • MAUNA KEA TECHNOLOGIES · PARISFrance
  • MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV · MUNCHENGermany
  • RAYFOS LTD · BASINGSTOKEUnited Kingdom
  • TAGWORKS PHARMACEUTICALS BV · NijmegenNetherlands
  • TECHNISCHE UNIVERSITAET MUENCHEN · MuenchenGermany
  • TECOBIOSCIENCES GMBH · LANDSHUTGermany
  • UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS · GoettingenGermany
  • UNIVERSITEIT MAASTRICHT · MaastrichtNetherlands

Links

Data: CORDIS, © European Union